Swedish Orphan Biovitrum SOBI.ST
Swedish Orphan Biovitrum (Sobi) is an international biopharmaceutical company focused on rare and specialized diseases, with a business model that combines internal development with licensing agreements to bring innovative treatments to patients. Sobi shows exceptional growth (revenue +27%, earnings +71.6%) supported by a developing pipeline, although its current valuation (P/E 110.74) already discounts much of that potential and its return on equity is weak (ROE 3.40%).
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Swedish Orphan Biovitrum (Sobi) is an international biopharmaceutical company focused on rare and specialized diseases, with a business model that combines internal development with licensing agreements to bring innovative treatments to patients. Sobi shows exceptional growth (revenue +27%, earnings +71.6%) supported by a developing pipeline, although its current valuation (P/E 110.74) already discounts much of that potential and its return on equity is weak (ROE 3.40%).
Score by category
| Category | Score |
|---|---|
| Financial health | 6.7 |
| Quality / Moat | 5.6 |
| Valuation | 4.4 |
| Growth | 9.2 |
| Dividend | 1.5 |
| Momentum | 8.6 |
| Risk & Context | 8.9 |
OVERALL SCORE: 6.4/10
Context and risks
Sobi operates in the pharmaceutical sector, subject to regulatory pressure on pricing and drug approvals. Governance risk in Sweden is moderate, but dependence on regulatory approvals for its pipeline (lacutamab, CTCL) adds uncertainty.
News considered in the analysis
- Sobi licenses Innate’s CTCL drug for up to $580m as it heads to Phase III — Acuerdo de licencia de hasta 580 millones de dólares que amplía el pipeline de Sobi en oncología, con potencial material si el fármaco supera la Fase III.
- Swedish Orphan Biovitrum (OM:SOBI) Following Its Lacutamab Deal And The Undervalued Narrative — Análisis que destaca el acuerdo de lacutamab y la narrativa de infravaloración; refuerza la percepción de potencial de crecimiento.
- Swedish Orphan Biovitrum (OM:SOBI) Stock Looks Strong On Returns But Fully Priced On Earnings — Artículo que señala que la acción está totalmente valorada en términos de beneficios, lo que sugiere un limitado margen de revalorización a corto plazo.
- Swedish Orphan Biovitrum AB (BIOVF) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and ... — Resultados del segundo trimestre con fuerte crecimiento de ingresos, consistente con la nota de crecimiento del 27%.
- Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue Estimates — Noticia sobre una compañía no relacionada; sin impacto para Sobi.
Verdict: Hold; strong growth and pipeline justify the premium, but demanding valuation and low return on capital limit appeal at these prices.
Main risk: Dependence on regulatory approvals and clinical trial success for its pipeline (lacutamab, CTCL) is the main risk, as a Phase III failure could erode the valuation premium.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →